Journal article
A multicenter, randomized, placebo‐controlled trial of atorvastatin for the primary prevention of cardiovascular events in patients with rheumatoid arthritis
- Abstract:
-
OBJECTIVE:Rheumatoid arthritis (RA) is associated with increased cardiovascular event (CVE) risk. The impact of statins in RA is not established. We assessed whether atorvastatin is superior to placebo for the primary prevention of CVE in RA patients. METHODS:Randomized, double-blind, placebo-controlled trial designed for 80% power at p<0.05 to detect a 32% CVE risk reduction based on an estimated 1.8% per annum (pa) event rate. Patients aged >50 years or with RA duration >10 years; ...
Expand abstract
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Bibliographic Details
- Publisher:
- Wiley Periodicals Publisher's website
- Journal:
- Arthritis and Rheumatology Journal website
- Volume:
- 71
- Issue:
- 9
- Pages:
- 1437-1449
- Publication date:
- 2019-04-15
- Acceptance date:
- 2019-02-19
- DOI:
- EISSN:
-
2326-5205
- ISSN:
-
2326-5191
- Pmid:
-
30983166
Item Description
- Language:
- English
- Keywords:
- Pubs id:
-
pubs:993231
- UUID:
-
uuid:8c581126-1716-40d1-a1b6-175f35f046cc
- Local pid:
- pubs:993231
- Source identifiers:
-
993231
- Deposit date:
- 2019-05-31
Terms of use
- Copyright holder:
- Kitas et al
- Copyright date:
- 2019
- Notes:
- © 2019 The Authors. Arthritis & Rheumatology, published by Wiley Periodicals, Inc. on behalf of American College of Rheumatology. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
- Licence:
- CC Attribution (CC BY)
Metrics
If you are the owner of this record, you can report an update to it here: Report update to this record